Study Design and Patient Population
After IRB approval, a retrospective chart review identified eligible
patients aged 25 years or younger. Patients were included if they were
diagnosed with any hematologic malignancy and received treatment with a
TPO-RA at any point in their clinical course from 2015 to 2023,
including during treatment at initial diagnosis, relapse, following
hematopoietic stem cell transplant (HCST) or CAR T-cell therapy.
Data were retrospectively extracted from electronic medical records,
including patient demographics, diagnosis, treatment history, TPO-RA
history, and clinical outcomes. Patients included in this case series
were not on a clinical trial; therefore, the selection of TPO-RA, dose,
and duration of treatment was based on clinician discretion.
Romiplostim was administered as a once weekly subcutaneous injection at
doses ranging from 1 mcg/kg to 10 mcg/kg. Eltrombopag was administered
as a daily tablet at doses ranging from 50mg to 150mg.